---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037982"
form_type: "8-K"
ticker: "ALEC"
cik: "0001653087"
company_name: "Alector, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:34:02.211309+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alector reports Q2 net income $1.4M, cash $630M; updates clinical trial timelines

## Summary
- Q2 2023 revenue $56.2M (down 30% YoY); net income $0.02 EPS vs $0.12 EPS in Q2 2022.
- Cash, equivalents & investments $630M, expected to fund operations through 2025.
- Guidance updated: 2023 collaboration revenue $90-100M (up), R&D $210-220M (down), G&A $60-65M.
- Invoke-2 Phase 2 (AL002) enrollment completion Q3 2023; data readout Q4 2024.
- INFRONT-3 pivotal trial enrollment completion expected Q4 2023; primary analysis on ~90-100 symptomatic FTD-GRN participants.

## SEC filing metadata
- accession: 0000950170-23-037982
- form_type: 8-K
- ticker: ALEC
- cik: 0001653087
- company_name: Alector, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1653087/000095017023037982/0000950170-23-037982-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1653087/000095017023037982/alec-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037982
- JSON: https://secwatch.observer/filing/0000950170-23-037982.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037982.txt

## Key facts
- Earnings Releases
  Alector, Inc. reported the quarter ended June 30, 2023 results: revenue $56.2 million.
  - Period: the quarter ended June 30, 2023
  - Revenue: $56.2 million
  - Result: reported results
  source text: quarter of 2023 covering AL002 compositions and methods of use. Second Quarter 2023 Financial Results Revenue. Collaboration revenue for the quarter ended June 30, 2023, was $56.2 million, compared to $79.9 million for the same period in 2022. The $23.6 million decrease was mainly due to $68.9 million of collaboration revenue recognized in the second quarter of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1653087/000095017023037982/0000950170-23-037982-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.